肠道微生物组在抑郁症中的新兴作用:对精准医学的启示
本文综述了肠道微生物组在重度抑郁症发病中的作用及其作为诊断和治疗靶点的潜力。文章总结了抑郁相关的微生物组成与功能改变,阐述了其致病机制,并评估了其作为新型诊断生物标志物和治疗靶点的可能性,最后展望了利用肠道微生物组推进抑郁症精准医学的未来前景。
要点
- 肠道微生物组与重度抑郁症的发病相关,其组成和功能改变与抑郁相关。
- 肠道微生物组有潜力作为抑郁症的诊断生物标志物和治疗靶点。
- 基于微生物组的精准医学是抑郁症未来诊疗的发展方向。
核心结论
- 肠道微生物组在抑郁症发病中起重要作用,并有望成为诊断和治疗靶点,推动基于微生物组的精准医学。
研究设计与样本
- 本文为综述,汇总了临床前和临床研究发现,总结抑郁相关的微生物组成与功能改变、机制贡献及诊疗潜力。
主要发现
- 临床前和临床研究发现肠道微生物组在抑郁症发病中起重要作用。
- 抑郁伴随微生物组成和功能的改变,这些改变通过特定机制参与疾病发病。
- 肠道微生物组有潜力作为新型诊断生物标志物和治疗靶点。
临床怎么用
- 深入理解肠道微生物组调控抑郁症的机制,可改善诊断和治疗策略。
- 利用肠道微生物组推进抑郁症的精准医学应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Major depressive disorder is a debilitating mental illness that seriously endangers human health. Its pathogenesis is highly complex, and traditional treatments face substantial challenges. A growing body of preclinical and clinical findings highlight the important role of the gut microbiome in the pathogenesis of depression and its potential as a diagnostic and therapeutic target. A deeper understanding of how the gut microbiome regulates depression will greatly enhance its clinical application, improve diagnostic and treatment strategies, and pave the way for microbiota-based precision medicine for depression. In this review, we summarize the depression-associated compositional and functional microbial alterations, delineate their mechanistic contributions to disease pathogenesis, and evaluate their potentiality as novel diagnostic biomarkers and treatment targets. Finally, we consider the future potential of utilizing the gut microbiome to advance precision medicine approaches for depression.
引用
- Liu L, Wang H, Guo S, et al. The emerging role of the gut microbiome in depression: implications for precision medicine. Mol Psychiatry. 2025. PMID: 40866540. doi:10.1038/s41380-025-03191-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。